A prolonged release Parenteral drug delivery system - An overview

International Journal of Pharmaceutical Sciences Review and Research

Volumn 3, Issue 1, 2010, Pages 1-11

  Bari, Hitesh ^a  

^a BHARATI VIDYAPEETH COLLEGE OF PHARMACY   (India)

Author keywords

In situ forming implant; In vitro testing devices; Liposomes; Microspheres; Solid lipid nanoparticle; Suspension

Indexed keywords

1 METHYL 2 PYRROLIDINONE; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; CAMPTOTHECIN; CARBOMER; CHITOSAN DERIVATIVE; CRYSTACILLIN; DAUNOSOME; DOXORUBICIN; GLYCEROL PALMITOSTEARATE; HYDROXYPROPYLMETHYLCELLULOSE; KETOPROFEN; LEUPRORELIN; LEVONORGESTREL; LIPOSOME; MACROGOL; MICROSPHERE; PACLITAXEL; POLOXAMER; POLY(N ISOPROPYLACRYLAMIDE); POLY(ORTHO ESTER); POLYACRYLIC ACID; POLYCAPROLACTONE; POLYGLACTIN; POLYLACTIC ACID; POLYMETHACRYLIC ACID; PREDNISOLONE; PROCAINE PENICILLIN; SOLID LIPID NANOPARTICLE; SPIRONOLACTONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEGETABLE OIL;

ADSORPTION; BIODEGRADABILITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SYNTHESIS; ENCAPSULATION; ESTERIFICATION; HUMAN; HYDROGEL; HYDROPHILICITY; IN VITRO STUDY; INJECTION SITE NECROSIS; INJECTION SITE PAIN; NONHUMAN; PATENT; REVIEW; SLOW RELEASE FORMULATION; SUSPENSION; SUSTAINED RELEASE PREPARATION;

EID: 79952025252     PISSN: None     EISSN: 0976044X     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Naik A, Kalia Y, Guy R, Transdermal drug delivery: overcoming the skin's barrier function, PSTT, 3(9), september 2000
2. Anderson BD, Chu WW, Galinsky RE, Reduction of first-pass metabolism of propranolol after oral administration of ester prodrug, International Journal of Pharmaceutics, 43(3), May 1988, 261-265
3. Shin Hyun, Bae Soo, Lee Myung, Pharmacokinetics of sidenafil after intravenous and oral administration in rats: Hepatic and intestinal first pass effects, International Journal of Pharmaceutics, 320, 2006, 64-70
4. Heller J, Polymers for controlled parenteral delivery of peptides and proteins, Advanced Drug Delivery Review, 10, 1993, 163-204
5. Langer R, New methods of drug delivery, Science, 249, 1990, 1527-1553
6. Tipton AJ, Dunn R, In situ gelling system, in: sustained release injectable product, Senior JH, Radomsky M, Interpharm press, Denver, 2000, 71- 102
7. Hollister LE, Site-specific drug delivery to central nervous system, Neurobiology Aging, 10, 1989, 628-631
8. Levy R J, Vinod L, Strickberger SA, Underwood T, Davis J, Controlled release implant dosage forms for cardiac arrhythmias: review and perspective, Drug delivery, 3, 1996, 137-142
9. Chen L, Apte RN, Cohen S, Characterization of PLGA microsphere for the controlled delivery of IL-1 for tumor immunotherapy, J Control Release, 43, 1997,261-272
10. Okada H, Docken Y, Ogawa Y, Toguchi H, Sustained suppression of the pituitary-gonadal axis by leuprorelin three month depot microspheres in rats and dogs, Pharm Res, 11, 1994, 199-203
11. Sinha V, Trehan A, Biodegradable microspheres for protein delivery, J Control Release, 90, 2003, 261-280
12. Park TG, Degradation of poly(lactic-co-glycolic acid) microspheres: effect of copolymer composition, Biomaterials, 16, 1995, 1123-1130
13. Allen TM, Hansen CB, Guo L, Subcutaneous administration of liposomes: a comparision with the intravenous and intraperitoneal routes of injection, Biochim. Biophys. Acta 1150, 1993, 9-16
14. Bonetti A, Chatelut E, Kim S, An extended-release formulation of methotrexate for subcutaneous administraton, Cancer Chemotherapy Pharmacology 1994;33:303-306
15. Sharma A, Sharma U, Liposomes in drug delivery: progress and limitations, International Journal of Pharmaceutics. 154, 1997, 123-140
16. Qiang Ye, Asherman J, Stevenson M, Brownson E, Katre N, Depo foam technology: a vehicle for controlled delivery of protein and peptide drug, J Control Release 64, 2000, 155-166
17. Mantripragada S, A lipid based depot(Depot Foam technology) for sustained release drug delivery, Progress in lipid research 41, 2002, 392-406
18. Haglund B, Joshi R, Himmelstein K, An in situ gelling system for parenteral delivery, J Control Release 41, 1996, 229-235
19. Motulsky A, Lafleur M, Hoarau D, Boury F, Characterization and biocompatibility of organogels based on L-alanine for parenteral drug delivery implants, Biomaterials 26, 2005, 6242-6253
20. Byeongmoon J, You Han Bae, Sung Wan Kim, Drug release from biodegradable injectable thermosensitive hydrogel of PEG-PLGA-PEG triblock copolymers, J Control Release 63, 2000, 155-163
21. Mingxi Qiao, Dawei Chen, Xichen Ma, Yanjun Liu, Injectable biodegradable temperature-responsive PLGA-PEG-PLGA copolymers: synthesis and effect of copolymer composition on the drug release from the copolymer-based hydrogels, International Journal of Pharmaceutics, 294, 2005, 103-112
22. Kwang-Mi Jin, Yong-Hee Kim, Injectable, thermoreversible and complex coacervate combination gels for protein drug delivery, J Control Release, 127, 2008, 249-256
23. Buckwater FH, Dickison HL, Journal of American Pharmaceutical Association (Sci. Ed.) 47, 1958, 661
24. Chang HC, Li L, C, Marsh KC, Tian Y, Parenteral sustained release dosage forms of butorphanol for dogs, International Journal of Pharmaceutics, 176, 1999, 147-156
25. Kranz H, bodmeier R A, novel in situ forming drug delivery system for controlled parenteral drug delivery, International Journal of Pharmaceutics, 332, 2007, 107-114
26. Larsen Claus, On the mechanism of drug release from oil suspensions in vitro using local anesthetics as model drug compounds, Euro. J. of Pharm. Sci., 34, 2008, 37-44
27. Fredholt Karin, Larsen Dorrit, Larsen Clause, Modification of in vitro drug release rate from oily parenteral depots using a formulation approach, Euro. J. of Pharm. Sci., 11, 2000, 231-237
28. Dorrit Bjerg Larsen, Stig Joergensen, Niels Vidiendal Olsen, Clause Larsen, In vitro release of bupivacaine from subcutaneously administered oily solution: comparison with in vitro release, J Control Release, 81, 2002, 145-154
29. Larsen Susan Weng, Jesper Ostergaard, Marit N, Jassen B, Clause Larsen, In vitro assessment of drug release rates from oil depot formulations intended for intra-articular administration, Euro. J. of Pharm. Sci., 29, 2006, 348-354
30. Wissing SA, Kayser O, Muller RH, Solid lipid nanoparticle for parenteral drug delivery, Advanced Drug Delivery Review, 56, 2004, 1257-1272
31. Joshi Medha, Muller Rainer, Lipid nanoparticles for parenteral delivery of actives, Euro. J. of Pharm. and Biopharm., 71, 2009, 161-172
32. Chien YW, Parenteral drug delivery and delivery systems, In: Novel drug delivery system, second Ed, 50, Marcel Dekker, New York, 382-385
33. Avis Kenneth, Sterile poduct, In: The theory and practice of industrial pharmacy, Lachman L, Lieberman H, Kanig J, Varghese publishing house, Bombay, 653-654
34. Bowersock Terry, Martin Stephen, Vaccine delivery to animals, Advanced Drug Delivery Review, 38, 1999, 167-194
35. Bezwada RS, Preparation of liquid copolymers of E- caprolactone and lactide, U S Patent 1995, 5:442,033
36. Moreau M, Schneider M, Boisramc B, Gurny R, Controlled delivery of metoclopramide using on injectable semisolid poly(orthoester) for veterinary application, International Journal of Pharmaceutics, 248(1-2), 2002, 31-37
37. Einmahl S, Behar-Cohen F, Tabatabay C, Hermies FD, Chauvaud D, Heller J, Gurny R, A viscous bioerodible poly(orthoester) as a new biomaterial for intraocular application, Journal Biomed Mater Res, 50, 2000, 566-577
38. Holland SJ, Tighe BJ, Gould PL, Polymers for biodegradable medical devices 1.The potential of polyesters as controlled macromolecular release system, J Control Release, 4, 1986, 155-180
39. Deshpande AA, Heller J, Gurny R, Bioerodible polymer for ocular drug delivery, Crit Rev Ther Drug Carrier Syst, 15(4), 1998, 381-420
40. Mali Mahesh, Hajare Ashok, Systems for sustained ocular drug delivery: a review of stimuli-sensitive in situ gel-forming systems, Euro J of parent & Pharm Sci, 14(3), 2009, 79-83
41. Zhang X, Jackson JK, Wang W, Min W, Cruz T, Hunter WL, Burt HM, Development of biodegradable polymeric paste formulation for Taxol: an in-vivo and in-vitro study, International Journal of Pharmaceutics, 137, 1996, 199-208
42. Alonso PE, Perula LA, Rioja LF. Pain-temperature relation in the application of local anesthesia, British J Plast Surg, 46(1), 1993, 76-78
43. Dunn RL, English JP, Cowsar DR, Vanderbelt DD, Biodegradable in-situ forming implants and method for producing the same, U S Patent 23Aug 1994, 5:340849
44. Saleem MA, Ahmed SI, Tephrosia purpurea ameliorates benzoyl peroxides-induced cutaneous toxicity in mice: diminution of oxidative stress, Pharm Pharmacol Commun, 5(7), 1999, 455-461
45. Sawhney AS, Pathak CP, Hubell JA, Bioerodible hydrogels based on photopolymeerized poly(ethyleneglycol)-copoly(alpha-hydroxy acid) diacrylate macromers, Macromolecules, 26(4), 1993, 581-587
46. Philbrook M, Lehnert S, Warnock D, Duan S, Enscore D, Tissue adherent depot for prevention of local tumor recurrence, Proceedings-27th International symposium of Controlled Release of Bioactive Materials, 2000, 510-511
47. West JL, Hubell JA, Localized intravascular protein delivery from photopolymerized hydrogels, Proc Int Symp Control Rel Bioact Mater, 22, 1995, 17-18
48. Chenite A et al, Novel injectable neutral solutions of chitosan form biodegradablegels in situ, Biomaterial, 21(21), 2000, 2155-2161
49. Cohen S, Lobel E, Trevgoda A, Peled Y, A novel, In situ-forming ophthalmic drug delivery system from alginates undergoing gelation in the eye, J Control Rel, 44(2-3), 1997, 201-208
50. Lansdown ABG, Payne MJ, An evaluation of the local reaction and biodegradation of calcium sodium alginate(Kaltostat) following subcutaneous implantation in the rat, J R Coll Surg Edinb, 39, 1994, 284-288
51. Dunn RL, English JP, Cowsar DR, Vanderbilt DP, Biodegradable in-situ forming implans and methods of producing the same, U S Patent 1990, 4,938,763
52. Dunn RL, The atrigel drug delivery system, In: Drugs and the pharmaceutical sciences, 126, Dekker, New York, MA, 2003, 647-655
53. Ravivarapu HB, Moyer KL, Dunn RL, Sustained activity and release of leuprolide acetate from an in situ forming polymeric implant, AAPS Pharm Sci Tech, 1(1), 2000
54. Radomsky ML, Brouwer G, Floy BJ, Loury DJ, Chu F, Tipton AJ, Sanders LM, The controlled release of Ganirelix from the Atrigel injectable implant system, Proc Intern Symp Control Rel Bioac. Material, 20, 1993
55. Lambert WJ, Peck KD, Development of an in situ forming biodegradable poly-lactide-co-glycolide system for the con- trolled release of proteins, J Control Release, 33, 1995, 189-195.
56. Shively ML, Bennett AT, Coonts BA, Renner WD, Southard JL, Physico-chemical characterization of polymeric injectable implant delivery system, J Control Release, 33, 1995, 237-243
57. Chandrashekar BL, Zhou M, Jarr EM, Dunn RL, Controlled release liquid delivery compositions with low initial drug burst, US Patent 2000, 6 143 314
58. Brodbeck KJ, Desnoyer JR, Mchugh AJ, Phase inversion dynamics of PLGA solutions related to drug delivery. Part II: The role of solution thermodynamics and bath-side mass transfer, J Control Release, 62(3), 1999, 333-344.
59. Graham PD, Brodbeck KJ, Mchugh AJ, Phase inversion dynamics of PLGA solutions related to drug delivery, J Control Release, 58(2), 1999, 233-245
60. Ismail FA, Napaporn J, Hughes JA, Brazeau GA, In situ gel formulations for gene delivery: release and myotoxdegradable icity studies, Pharm Dev Tech, 5, 2000, 391-397
61. Stile RA, Burghardt WR, Healy KE, Synthesis and characterization of injectable poly(N-isopropylacrylamide)-based hydrogels that support tissue formation in vitro, Macromolecules, 32(22), 1999, 7370-7379.
62. Merril EW, Pekala RW, Hydrogel for blood contact, in: Hydrogels in Medicine and Pharmacy, Peppas NA, Vol. III., CRC Press, 1987
63. Jeong B, Bae YH, Lee DS, Kim SW, Biodegradable block copolymers as injectable drug delivery systems, Nature, 388, 1997, 860-862
64. Bochot A, Fattal E, Gulik A, Couarraze G, Couvreur P, Liposomes dispersed within a thermosensitive gel: a new dosage form for ocular delivery of oligonucleotides, Pharm Res, 15 (9), 1998, 1364-1369
65. Yong CS, Choi JS, Quan QZ, Rhee JD, Kim CK, Lim SJ, Kim KM, Oh PS, Choi HG, Effect of sodium chloride on the gelation temperature, gel strength and bioadhesive force of poloxamer gels containing diclofenac sodium, International Journal of Pharmaceutics, 226(1-2), 2001, 195-205.
66. Joshi A, Ding S, Himmelstrin KJ, Reversible gelation compositions and methods of use, U S Patent 12th October 1993, 5 252 318.
67. Jeong B, Bae YH, Lee DS, Kim SW, Biodegradable block copolymers as injectable drug-delivery systems, Nature, 388(6645), 1997, 860-862
68. Jeong B, Choi YK, Bae YH, Zentner G, Kim SW, New biodegradable polymers for injectable drug delivery systems, J Control Release, 62(1-2), 1999, 109-114.
69. Jeong Byeongamoon, Bae You Han, Kim Sung Wan, Drug release from biodegradable injectable thermosensitive hydrogel of PEG-PLGA-PEG triblock copolymer, J Control Release, 63, 2000, 155-163.
70. Ruel-Gariepy E, Leclair G, Hildgen P, Gupta A, Leroux JC, Thermosensitive chitosan based hydrogel containing liposomes for the delivery of hydrophilic molecules, J Control Release, 82, 2002, 373-383
71. Engstrom S, Engstrom L, Phase behavior of the lidocaine- monoolein-water system, International Journal of Pharmaceutics, 79, 1992, 113-122
72. Bergh Van Den, Gregoriadis G, Water-in-sorbitan monostearate organogels (water-in-oil gels), J Pharm Sci 88, 1999, 615-619
73. Murdan S, Gregoriadis G, Florence AT, Sorbitan monostearate/polysorbate20 organogels containing neosomes: a delivery vehicle for antigens?, Euro J of Pharm Sci, 8, 1999, 177-186
74. Gao Z, Shukla AJ, Johnson JR, Crowley WR, Controlled release of contraceptive steroid from biodegradable and injectable gel formulations: in- vitro evaluation, Pharm Res, 12(6), 1995, 857-864
75. Gao Z, Crowley WR, Shukla AJ, Johnson JR, Reger JF, Controlled release of contraceptive steroids from biodegradable and injectable gel formulations: in-vivo evaluation, Pharm Res, 12(6), 1998, 864-868
76. Plourde F, Motulsky A, Couffin-Hoarau AC et al, First report on the efficacy of L-alanine based in situ forming impants for the long term parenteral delivery of drugs, J Control Release, 108, 2005, 433-441.
77. Kissel T, Li YX, Volland C, GSrich S, Koneberg R, Parenteral protein delivery systems using biodegradable polyesters of ABA block structure, containing hydrophobic poly(lactide-co-glycolide) A blocks and hydrophilic poly (ethylene oxide) B blocks, J Control Release, 39, 1996, 315-326
78. Okada Hiroaki, One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate, Advanced Drug Delivery Reviews, 28, 1997, 43-70
79. Takada Shigeyuki, Kurokawa Tomofumi, Miyazaki Keiko, Iwasa Susumu, Ogawa Yasuaki, Sustained release of a water-soluble GP IIb/IIIa antagonist from copoly (DL-lactic/glycolic) acid microspheres, International Journal of Pharmaceutics, 146, 1997, 147-157
80. Chena L, Apteb Ron, Cohen Smadar, Characterization of PLGA microspheres for the controlled delivery of IL-1a for tumor immunotherapy, J Control Release, 43, 1997, 261-272
81. Genta I, Perugini P, Pavanetto F, Maculotti K, Modena T, Casado B, Lupib A, Iadarolab P, Conti B, Enzyme loaded biodegradable microspheres in vitro ex vivo evaluation, J Control Release, 77, 2001, 287-295
82. Diez Sonsoles, Ilarduya Tros de Conchita, Versatility of biodegradable poly (D,L-lactic-co-glycolic acid) microspheres for plasmid DNA delivery, Euro J of Pharm and Biopharm, 63, 2006, 188-197
83. Gabizon A, Barenholz Y, Liposomal anthracyclines- from basics to clinical approval of PEGylated liposomal doxorubicin, In: Liposomes: rational design, Janoff AS, Marcel Dekker, New York, 1999; 343-362.
84. Sankaram MB, Commercial sustained-release injectable formulations by encapsulation, In: Sustained-release injectable products, Senior J. and Radomsky M, Interpharm Press, Denver, CO, 2000, 25-39
85. Chiron Corporation, Physicians' Desk Reference, 54, 2000, 935-938
86. Langston Melissa, Ramprasad MP, Kararli TT, Galluppi GR, Katre NV, Modulation of the sustained delivery of myelopoietin (Leridistim) encapsulated in multivesicular liposomes (Depo Foam), J Control Release, 89, 2003, 87-99
87. Tian W, Schulze S, Brandl M, Winter G, Vesicular phospholipid gel-based depot formulations for pharmaceutical proteins: Development and in vitro evaluation, J Control Release, 2009; (article in press)
88. Holger Grohganz, Ingunn Tho, Martin Brandl, Development and in vitro evaluation of a liposome based implant formulation for the decapeptide Cetrorelix, Euro J of Pharm and Biopharm, 59, 2005, 439-448
89. Davis JM, Matalon L, Watanable MD, Blake L, Depot antipsychotic drugs, place in therapy, Drugs, 47, 1994, 741-773
90. Hallas-Moller K, Peterson K, Schlichikrull J, Crystalline and amorphous insulin-zinc compounds with prolonged action, Science, 116, 1952, 394-398
91. Yoshiya Yamahiza, Keiji Fujioka, Sustained-release IFN preparation for parentaral administration, European Patent EP, 1st July 1993, 0138216
92. Kipp JE, The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs, International Journal of Pharmaceutics, 284, 2004, 109-122
93. Muhlen A, Mehnert W, Drug release and release mechanism of prednisolone loaded solid lipid nanoparticles, PharmaZie, 53, 1998, 552
94. Vgazio E, Cavalli R, Gsaco MR, Incorporation of Cyclosporin A in solid lipid nanoparticles, International Journal of Pharmaceutics, 241, 2002, 341-344
95. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ, Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain, J Control Release, 59, 1999, 299-307
96. Schultz K, Mollgaard B, Frokjaer S, Larsen C, Rotating dialysis cell as in vitro release method for oily parenteral depot solutions, International Journal of Pharmaceutics, 157, 1997, 163-169
97. Soderberg L, Dyhre H, Roth B, Bjorkman S, The "inverted cup" - A novel in vitro release technique for drugs in lipid formulations, J Control Release, 113, 2006, 80-88